This site uses cookies to improve the browsing experience. Please visit our Privacy Policy page for more information.
Privacy Policy
firefly
FIREFLY-1:
DAY101, an investigational, oral, pan-RAF inhibitor being studied in pediatric patients with recurrent or progressive low-grade glioma and advanced solid tumors with RAF alterations
firelight
FIRELIGHT-1:
DAY101, an investigational, oral, pan-RAF inhibitor being studied in adolescent and adult patients with recurrent or progressive solid tumors with MAPK pathway alterations
Interested in learning more?
Click here to contact a member of the Day One Clinical team